These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35483398)

  • 1. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.
    Thanarajasingam G; Minasian LM; Bhatnagar V; Cavalli F; De Claro RA; Dueck AC; El-Galaly TC; Everest N; Geissler J; Gisselbrecht C; Gormley N; Gribben J; Horowitz M; Ivy SP; Jacobson CA; Keating A; Kluetz PG; Kwong YL; Little RF; Matasar MJ; Mateos MV; McCullough K; Miller RS; Mohty M; Moreau P; Morton LM; Nagai S; Nair A; Nastoupil L; Robertson K; Sidana S; Smedby KE; Sonneveld P; Tzogani K; van Leeuwen FE; Velikova G; Villa D; Wingard JR; Seymour JF; Habermann TM
    Lancet Haematol; 2022 May; 9(5):e374-e384. PubMed ID: 35483398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.
    Thanarajasingam G; Minasian LM; Baron F; Cavalli F; De Claro RA; Dueck AC; El-Galaly TC; Everest N; Geissler J; Gisselbrecht C; Gribben J; Horowitz M; Ivy SP; Jacobson CA; Keating A; Kluetz PG; Krauss A; Kwong YL; Little RF; Mahon FX; Matasar MJ; Mateos MV; McCullough K; Miller RS; Mohty M; Moreau P; Morton LM; Nagai S; Rule S; Sloan J; Sonneveld P; Thompson CA; Tzogani K; van Leeuwen FE; Velikova G; Villa D; Wingard JR; Wintrich S; Seymour JF; Habermann TM
    Lancet Haematol; 2018 Nov; 5(11):e563-e598. PubMed ID: 29907552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
    Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
    Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Kidney diseases associated with haematological cancers.
    Ganguli A; Sawinski D; Berns JS
    Nat Rev Nephrol; 2015 Aug; 11(8):478-90. PubMed ID: 26035773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiotoxicity of Targeted Therapies in Children with Haematological Malignancies and Solid Tumors.
    Bangeas A; Tragiannidis A
    Anticancer Agents Med Chem; 2023; 23(15):1702-1709. PubMed ID: 37231721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.
    Thanarajasingam G; Leonard JP; Witzig TE; Habermann TM; Blum KA; Bartlett NL; Flowers CR; Pitcher BN; Jung SH; Atherton PJ; Tan A; Novotny PJ; Dueck AC
    Lancet Haematol; 2020 Jun; 7(6):e490-e497. PubMed ID: 32470440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.
    Sethi TK; Basdag B; Bhatia N; Moslehi J; Reddy NM
    Curr Hematol Malig Rep; 2017 Jun; 12(3):257-267. PubMed ID: 28233150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial.
    Mullane KM; Morrison VA; Camacho LH; Arvin A; McNeil SA; Durrand J; Campbell B; Su SC; Chan ISF; Parrino J; Kaplan SS; Popmihajlov Z; Annunziato PW;
    Lancet Infect Dis; 2019 Sep; 19(9):1001-1012. PubMed ID: 31399378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of drug-drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs.
    Brüggemann RJ; Verheggen R; Boerrigter E; Stanzani M; Verweij PE; Blijlevens NMA; Lewis RE
    Lancet Haematol; 2022 Jan; 9(1):e58-e72. PubMed ID: 34890539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ferroptosis in Haematological Malignancies and Associated Therapeutic Nanotechnologies.
    Mynott RL; Habib A; Best OG; Wallington-Gates CT
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland.
    Tiihonen J; Tanskanen A; Bell JS; Dawson JL; Kataja V; Taipale H
    Lancet Psychiatry; 2022 May; 9(5):353-362. PubMed ID: 35334224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting infections in patients with haematological malignancies treated with chimeric antigen receptor T-cell therapies: A systematic scoping review and narrative synthesis.
    Reynolds G; Sim B; Anderson MA; Spelman T; Teh BW; Slavin MA; Thursky KA
    Clin Microbiol Infect; 2023 Oct; 29(10):1280-1288. PubMed ID: 37201866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights.
    Shibata T; Nohara S; Morikawa N; Shibao K; Ito S; Shibata R; Toh U; Nagafuji K; Fukami K; Fukumoto Y
    Eur J Prev Cardiol; 2023 Dec; 30(18):1941-1949. PubMed ID: 37352112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anorexia and weight loss in long-term survivors of haematological malignancies.
    Molassiotis A
    J Clin Nurs; 2003 Nov; 12(6):925-7. PubMed ID: 14632985
    [No Abstract]   [Full Text] [Related]  

  • 15. Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial.
    Aguilar-Guisado M; Espigado I; Martín-Peña A; Gudiol C; Royo-Cebrecos C; Falantes J; Vázquez-López L; Montero MI; Rosso-Fernández C; de la Luz Martino M; Parody R; González-Campos J; Garzón-López S; Calderón-Cabrera C; Barba P; Rodríguez N; Rovira M; Montero-Mateos E; Carratalá J; Pérez-Simón JA; Cisneros JM
    Lancet Haematol; 2017 Dec; 4(12):e573-e583. PubMed ID: 29153975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucositis in the treatment of haematological malignancies.
    Niscola P; Scaramucci L; Romani C; Cupelli L; Tendas A; Dentamaro T; Ales M; Giovannini M; Piccioni D; Siniscalchi A; Tolu B; Perrotti A; Keefe D; de Fabritiis P
    Ann Oncol; 2008 Sep; 19 Suppl 7():vii141-5. PubMed ID: 18790936
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of the safety and efficacy of low-dose rasburicase in critically ill children with haematological malignancies.
    Pei Y; Li Y; Liang Y; Xu L; Huang X; Li Y; Tang W; Jiang X
    Int J Clin Pharm; 2020 Dec; 42(6):1440-1446. PubMed ID: 32974856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.
    Jelinek T; Mihalyova J; Kascak M; Duras J; Hajek R
    Immunology; 2017 Nov; 152(3):357-371. PubMed ID: 28685821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of patients receiving chemotherapy for haematological malignancies to scabies.
    Hosoi H; Nishikawa S; Kida Y; Kishi T; Murata S; Iwamoto M; Toyoda Y; Yamada Y; Ikeda T; Sonoki T
    J Hosp Infect; 2020 Nov; 106(3):594-599. PubMed ID: 32866631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.